Ertumaxomab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Trifunctional antibody |
| Source | Rat/mouse hybrid |
| Target | HER2/neu, CD3 |
| Clinical data | |
| Trade names | Rexomun |
| Identifiers | |
| CAS Number | 509077-99-0  |
| ATC code | none |
 (what is this?) (verify) |
|
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[1]
It is a so-called trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[2]
Adverse drug effects
Lua error in package.lua at line 80: module 'strict' not found.
References
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles using small message boxes
- Monoclonal antibodies for tumors
- Immunology
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
